Stock performance snapshot

Protagonist Therapeutics (PTGX) has drawn attention after recent share price moves, with the stock last closing at US$99.19 and showing a mix of shorter term pullbacks and longer term gains.

Over the past day the stock declined 2.8%, while over the past week it inched up 0.8%. Performance over the past month is slightly down 0.8%, while the past 3 months show a gain of 13.9% and the past year a total return of 113.6%.

For context, the recent 1-day share price pullback comes after a strong run, with the year-to-date share price return in double digits and the 1-year total shareholder return above 100%, hinting at momentum built over a longer period.

If you are looking beyond a single biotech story, this is a useful moment to broaden your watchlist with 34 healthcare AI stocks.

With Protagonist Therapeutics still loss making but carrying a market value of about US$6.4b, the real question is whether the current price reflects all that pipeline potential or if the market is leaving any upside on the table.

Preferred Price to Book of 9.7x: Is it justified?

On traditional valuation, Protagonist Therapeutics looks expensive at first glance, with a P/B of 9.7x at a last close of $99.19, yet some comparative signals tell a more nuanced story.

P/B compares the company’s market value to its accounting book value. It is often used for asset light, research heavy biotechs where earnings are still negative. For a loss making business like Protagonist Therapeutics, investors typically focus on balance sheet strength and the value the market assigns to its pipeline and intellectual property rather than current profits.

Against the broader US Biotechs industry, Protagonist Therapeutics trades at a much higher P/B than the 2.5x average. This suggests investors are paying a premium relative to typical peers. However, when stacked against a closer peer group, its 9.7x P/B sits below the peer average of 12.7x, indicating the market is not applying the highest premium within that set and may be pricing its prospects more cautiously than some direct comparables.

Result: Price to book of 9.7x (OVERVALUED).

However, investors still face clear risks, including clinical setbacks across the pipeline and ongoing losses of US$114.7m, which may require further funding on uncertain terms.

Another view: DCF suggests a very different story

While the 9.7x P/B ratio flags the stock as expensive on assets, the SWS DCF model points the other way. With the share price at $99.19 versus an estimated future cash flow value of $379.83, this approach frames PTGX as trading at a steep discount.

If book value says expensive but cash flow math points to upside, it raises a simple question for you: which lens do you trust more for a loss making biotech at this stage of its journey?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Protagonist Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals across valuation and cash flow, the story here is not straightforward. Treat this as your cue to move quickly, review the data, and weigh both the potential upside and the red flags using 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If PTGX has caught your eye, do not stop here. This is the moment to line up a few more candidates so you are ready when opportunities appear.

• Target potential mispricings by scanning 46 high quality undervalued stocks that combine quality fundamentals with prices the market may not fully appreciate yet.
• Prioritise resilience by checking out 66 resilient stocks with low risk scores designed for investors who want steadier profiles over aggressive swings.
• Spot future standouts early through the screener containing 21 high quality undiscovered gems and get familiar with companies that have strong metrics but limited mainstream attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.